Volume 3.17 | May 8

Pulmonary Cell News 3.17 May 8, 2014
Pulmonary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
Protein Molecule May Improve Survival in Deadly Lung Disease
Researchers have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis. [Press release from the University of Illinois at Chicago College of Medicine discussing online prepublication in the American Journal of Respiratory and Critical Care Medicine] Press Release | Abstract
Got cells? Jumpstart your research with ready to use immune and hematopoietic cells.
PUBLICATIONS (Ranked by impact factor of the journal)
Gene Expression Profile and Toxic Effects in Human Bronchial Epithelial Cells Exposed to Zearalenone
Scientists identified the responses and underlying molecular changes that occur when human bronchial epithelial BEAS-2B cells are exposed to zearalenone. [PLoS One] Full Article

The Use of a Three-Dimensional Cell Culture Model to Investigate Host-Pathogen Interactions of Francisella tularensis in Human Lung Epithelial Cells
Scientists investigated a three-dimensional cell-culture system to characterize the epithelial response to F. tularensis. Immortalized human pneumocytes grown in rotating-wall vessel bioreactors display an in vivo-like phenotype, which has been confirmed to be driven by specific transcriptional events. [Microbes Infect] Abstract

Cigarette Smoke Alters Non-Neuronal Cholinergic System Components Inducing MUC5AC Production in the H292 Cell Line
Mucin 5AC (MUC5AC), muscarinic acetylcholine receptor M3, choline acetyl-transferase, acetylcholine expression and acetylcholine binding significantly increased in H292 cells stimulated with cigarette smoke extract compared to untreated cells. [Eur J Pharmacol] Abstract

Effect of Thymic Stromal Lymphopoietin on MUC5B Expression in Human Airway Epithelial Cells
The effects and brief signaling pathways of thymic stromal lymphopoietin on expression of mucin genes in human airway epithelial cells were investigated in this study. [Biochem Biophys Res Commun] Abstract


Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Inhibitory effects of the aromatase inhibitor exemestane were assessed in lung adenocarcinoma cell lines that have EGFR mutations, separately and combined with EGFR tyrosine kinase inhibitor erlotinib. [Clin Cancer Res] Abstract

Co-Delivery of Doxorubicin and Paclitaxel by PEG-Polypeptide Nanovehicle for the Treatment of Non-Small Cell Lung Cancer
In vitro cytotoxicity assays against A549 human lung adenocarcinoma cell line demonstrated that the doxorubicin + paclitaxel co-delivered nanoparticles exhibited synergistic effect in inducing cancer cell apoptosis. [Biomaterials] Abstract

Inhibition of SIRT1 Signaling Sensitizes the Antitumor Activity of Silybin against Human Lung Adenocarcinoma Cells In Vitro and In Vivo
Researchers investigated the antitumor activity of silybin towards human lung adenocarcinoma cells in vitro and in vivo and explored the role of the silent information regulator 1 (SIRT1) signaling pathway in this process. [Mol Cancer Ther] Abstract

Grape Seed Proanthocyanidins Inhibit Cigarette Smoke Condensate-Induced Lung Cancer Cell Migration through Inhibition of NADPH Oxidase and Reduction in the Binding of p22phox and p47phox Proteins
Researchers report that grape seed proanthocyanidins exert an inhibitory effect on the cigarette smoke condensate-induced migration of non-small cell lung cancer cells. [Mol Carcinog] Abstract

Aquaporin 3 Knockdown Suppresses Tumor Growth and Angiogenesis in Experimental Non-Small Cell Lung Cancer
Scientists tested the anti-tumor effects of short hairpin RNA targeting aquaporin 3 (AQP3) in experimental non-small-cell lung cancer (NSCLC). AQP3 expression was suppressed in human A549 and H1299 NSCLC cell lines by short hairpin RNA-mediated silencing. [Exp Physiol] Abstract

Model the Human Respiratory Epithelium with PneumaCult™-ALI. Click to View Data.
Treatment of Small Cell Lung Cancer
Treatment of small cell lung cancer remains a significant challenge for the oncologists. Attempts to improve the results of first-line treatment have all failed so far and no real progress has been made in last years, emphasizing the need for novel strategies of treatment and the development of validated biomarkers. [Crit Rev Oncol Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Addition of VX-661 to KALYDECO® (Ivacaftor) Improves Lung Function in People with CF who Are Heterozygous for the F508del and G551D Mutations in 28-Day Phase II Proof-of-Concept Study
Vertex Pharmaceuticals Incorporated announced that treatment with the combination of VX-661 and KALYDECO® (ivacaftor) in a 28-day Phase II study showed statistically significant improvements in lung function in people with both the F508del mutation and G551D mutation who were already taking KALYDECO. [Vertex Pharmaceuticals Incorporated] Press Release

Pulmatrix’s PUR0200 Demonstrated Encouraging Results in Phase IB Clinical Study in COPD Patients
Pulmatrix announced the successful completion and positive results of the second part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate, PUR0200. [Press release from Pulmatrix, Inc. discussing research presented at the 2014 Respiratory Drug Delivery (RDD) Conference, Puerto Rico] Press Release

Synta Announces Results from Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC
Synta Pharmaceuticals Corp. announced final results from the GALAXY-1 trial, a global, randomized, multi-center study designed to identify the patients with advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology most likely to benefit from second-line treatment with the Company’s lead drug candidate, the Hsp90 inhibitor ganetespib, in combination with docetaxel versus docetaxel alone. [Synta Pharmaceuticals Corp.] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
MEI Pharma Initiates Clinical Study of Mitochondrial Inhibitor Drug Candidate ME-344 in Small Cell Lung and Ovarian Cancers
MEI Pharma, Inc. announced that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin® (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers. [MEI Pharma, Inc.] Press Release

Daiichi Sankyo Announces Discontinuation of Phase III Clinical Trial in Japan of Nimotuzumab (DE-766) in Lung Cancer
Daiichi Sankyo Company, Limited announced the discontinuation of the Phase III clinical trial conducted in Japan for nimotuzumab in Lung Cancer. The Phase III clinical trial was a multicenter, randomized, double-blind, placebo-controlled study investigating nimotuzumab for first-line therapy in patients with unresectable and locally advanced squamous cell lung cancer. [Daiichi Sankyo Company, Limited] Press Release

UGA to Use $5 Million Gift to Support Center for Molecular Medicine
A $5 million gift to support the Center for Molecular Medicine at the University of Georgia (UGA) will allow the institution to greatly advance its research into human disease. [University of Georgia] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 2014 Pittsburgh-Munich International Lung Conference
October 23-24, 2014
Pittsburgh, United States

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW Research Fellow – Pulmonary Cancer (Mayo Clinic – Rochester)

Postdoctoral Researcher – Metabolomics of Pulmonary Medicine (Karolinska Institute)

Molecular Immunologist – COPD (GlaxoSmithKline)

Postdoctoral Research Associate – Lung Injury and Repair (University of Illinois)

Postdoctoral Scholar – Molecular Mechanisms of Lung Cancer, Lung Regeneration and Lung Development (University of California, San Francisco)

Postdoctoral Opportunity – Mucins, Mucus and Mucociliary Interactions in the Lung (AstraZeneca)

Postdoctoral Positions – Pulmonary and Exercise Immunology (São Paulo Research Foundation)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Research Technologist – hPSC (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Pulmonary Cell News: Archives | Events | Contact Us